Celemics is trading at 3190.00 as of the 17th of March 2025, a 4.93 percent increase since the beginning of the trading day. The stock's open price was 3040.0. Celemics has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Celemics, Inc. designs, manufactures, and distributes sequencing kits. The company was founded in 2010 and is based in Seoul, South Korea. Celemics is traded on Korean Securities Dealers Automated Quotations in South Korea. More on Celemics
Although Celemics' alpha and beta are two of the key measurements used to evaluate Celemics' performance over the market, the standard measures of volatility play an important role as well.
Our tools can tell you how much better you can do entering a position in Celemics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Positions Ratings Now
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Celemics financial ratios help investors to determine whether Celemics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celemics with respect to the benefits of owning Celemics security.